Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/940945


Serbia Pharmaceuticals and Healthcare Report Q1 2011


Description: The Serbia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Serbia's pharmaceuticals and healthcare industry.

BMI expects Serbia’s total drug expenditure to reach RSD76.90bn (US$1.05bn) in 2010, when it will comprise 2.85% of the country’s GDP. However, per-capita drug expenditure will fall from US$148 in 2009 to US$144, due to local currency depreciation. Between 2009 and 2014, the Serbian pharmaceutical market is expected to expand at a compound annual growth rate (CAGR) of 7.66% in local currency and at just 4.69% in US dollar terms.

In the Q111 update of BMI’s Pharmaceuticals and Healthcare Business Environment Ratings (BERs), Serbia continues to rank in the lower half of the index with a reduced score of 44.6 out of 100, which places the country 16th of the 20 markets surveyed in the Central and Eastern European (CEE) region. The development of the Serbian pharmaceutical market is closely linked to stability in the country’s economic and political climate. Any economic or political destabilisation might negatively affect pharmaceutical market growth, as the spending power of both the state and the population would be adversely affected. Compared with other CEE countries, Serbia’s political and economic situation is delicate and there are no definite time horizons in terms of its European Union (EU) accession process.

In 2009, pharmaceutical imports decreased significantly by 47.4% to US$334.5mn, following an above expected increase of 30.2% y-o-y to US$636mn in 2008. However, from other available market data, BMI believes pharmaceutical expenditure at consumer prices was positive in 2009 and will continue to grow in 2010. The value of the local dinar is also a concern, although its rapid appreciation in recent years indicated that foreign investors were still willing to gamble on the potentially lucrative Serbian economy. However, dinar depreciation is expected in the coming years, foreign activities in Serbia may become more sluggish.

In September 2010, German drug company Stada Arzneimittel announced a partial halt in drug sales in Serbia, following fears over the inability of Serbian wholesalers to pay their bills. The current situation arose as state-run Serbian hospitals are either not paying or delaying their payments to wholesalers.


Contents: Executive Summary
SWOT Analysis
Serbia Pharmaceuticals And Healthcare Industry SWOT
Serbia Political SWOT
Serbia Economic SWOT
Serbia Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Emerging Europe Regional Pharma Business Environment Ratings for Q111
Rewards
Risks
Serbia – Market Summary
Regulatory Regime
Table: The Number of Products on the Drugs List
Intellectual Property Environment
Pricing Regime
Price Cuts
Price Rises
Reimbursement Regime
Table: Reimbursement by ATC Categories in 2008 and 2009
Table: Serbia – Examples of Reimbursed Medicines by Category
Industry Developments
Epidemiology
Communicable Diseases
Non-Communicable Diseases
Table: Disease Burden In CEE
Healthcare Sector
Table: Serbia – Major General And Specialised Hospitals

Recent Healthcare Sector Developments
Healthcare Insurance
Healthcare Reform
Medical Tourism
Table: Serbia – Cosmetic Surgery Costs
Clinical Trials
Medical Devices
Table: Medical Device Classification In Serbia

Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales Indicators 2006-2014
Table: Healthcare Expenditure Trends, Historical Data and Forecasts, 2006-2014
Key Growth Factors – Macroeconomic
Table: Serbia – Economic Activity

Prescription Drug Market Forecast
Table: Serbia – Defined Daily Dose (DDD) Per 1,000 Inhabitants
Table: Prescription Drug Sales Indicators 2006-2014
Patented Drug Market Forecast
Table: Patented Drug Sales Indicators 2006-2014
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2006-2014
OTC Medicine Market Forecast
Table: Serbia – Sales Of Herbal Remedies 2007
Table: OTC Medicine Sales Indicators 2006-2014
Medical Device Market Forecast
Table: Medical Device Sales Indicators 2006-2014
Pharmaceutical Trade Forecast
Table: Pharmaceutical Imports & Exports Indicators 2006-2014
Other Healthcare Data Forecasts
Key Risks to BMI’s Forecast Scenario
Competitive Landscape
Investment Climate
Pharmaceutical Industry
Table: Companies Involved In The Serbian Pharmaceutical Industry
Domestic Pharmaceutical Industry
Domestic Company Activity
Foreign Pharmaceutical Industry
Table: Proposed Members Of Serbia’s Pharmaceutical Industry Association
Foreign Company Activity
Pharmaceutical Wholesale And Retail

Company Monitor

Indigenous Company Profiles
Hemofarm (Stada)
Galenika
Zdravlje Actavis
Jugoremedija

Multinational Company Profiles
Pfizer
GlaxoSmithKline
Novartis
Sanofi-Aventis
Merck & Co
Krka

Country Snapshot: Serbia Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2000/01
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Average Annual Manufacturing Wages, 2000-2012

BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings System
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources


Companies Mentioned - Pfizer - GlaxoSmithKline - Novartis - Sanofi-Aventis - Merck & Co - Hemofarm (Stada) - Galenika - Zdravlje Actavis - Jugoremedija


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/940945

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 17/02/2012 03:38:06
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Serbia Pharmaceuticals and Healthcare Report Q1 2011
Web Address:
http://www.researchandmarkets.com/reports/940945
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €393.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 17/02/2012 03:38:06

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)